MCAM and Impaired glucose tolerance: Likewise, the ex vivo administration of pioglitazone of early (Dil-acLDL+ FITC‐UEA‐I+ KDR+CD31+CD146+ vWF+CD45+CD14+) and late EPCs (Dil-acLDL+ FITC‐UEA‐I+ KDR+CD31+CD146+vWF+) isolated from individuals with impaired glucose tolerance, increased viability and their tube forming ability while reduced the expression of pro-inflammatory markers (ICAM-1, VCAM-1, TNF-α) [177].